Peter McCarthy
Mr. McCarthy is now in his 7th year at Henry Schein, Inc. He is currently the Company's President, Global Animal Health Group, as well as a member of Henry Schein's Executive Management Committee.
Mr. McCarthy oversees Henry Schein's animal health business, which spans 24 countries including the United States, Australia, New Zealand, Canada, China, Malaysia, Brazil and 17 countries in Europe.
Before assuming his current position, Mr. McCarthy held key roles at Henry Schein with increasing responsibilities, including President, Henry Schein Animal Health, Europe, and President, Henry Schein Animal Health, International.
Prior to joining Henry Schein, Mr. McCarthy worked at Schering-Plough Animal Health (now Merck Animal Health), serving as Senior Director, Global Operations and General Manager, China. Mr. McCarthy also worked at Wyeth/American Cyanamid for 14 years, helping to grow the human pharmaceutical business.
Mr. McCarthy holds a degree in Applied Biology from the University of Hertfordshire in the U.K., and previously has served as a Member of the Board of the International Federation for Animal Health Europe, and the International Association Executive Animal Health Study Center, CEESA, based in Belgium. Mr. McCarthy is also a graduate and member of the Chartered Institute of Marketing (CIM), which is located in the U.K.
Pascale Jordan
Pascale Jordan got her PhD in Molecular and Cellular Biology from the Orsay University in France. She has nearly 20 years of experience in the Biotech/Pharma Industry, both Human and Animal Health. Pascale has served in a variety of roles, including Financial Analyst in Merchant Bank and Business Development Manager at Inserm Transfert, one of the leading Tech Transfer Office in France. Her last position was Business Development Director at Zoetis for the EuAfME region. She is now working as Business Development Director at Bio-Sourcing.
Kathrin Ladetzki-Baehs
Dr. Kathrin Ladetzki-Baehs joined MorphoSys > 10 years ago as a scientist. Following several years of intense laboratory work in antibody generation as a project team leader, she became an alliance manger in 2012.
Today, Kathrin (Director at MorphoSys) coordinates multiple therapeutic antibody projects in close collaboration with international external partners at MorphoSys.
Kathrin is a pharmacist and received the PhD from Ludwig Maximilians University Munich. Two dogs are beloved family members in Kathrin’s home. As one the dogs got diagnosed with canine cancer, Kathrin came up with the idea to transfer the whole expertise and knowledge of phage display, library generation and antibody generation from MorphoSys into the veterinary field. Since then she is responsible for all activities necessary to found adivo.
Karin Hoelzer
Karin Hoelzer is a senior officer in health programs supporting Pew’s safe food and antibiotic resistance projects. Hoelzer, a veterinarian by training, focuses on research and policies related to foodborne pathogens, the use of antibiotics in animals, and other public health risks related to the food supply.
Before joining Pew, Hoelzer worked at the U.S. Food and Drug Administration, where she developed and led risk assessments and conducted systematic reviews and meta-analyses on a variety of issues, such as drug residues in dairy products and Listeria monocytogenes in retail delicatessens. Previously, she was a research associate at Cornell University, where she traced the transmission of pathogens between livestock and humans.
Hoelzer holds doctorates in veterinary medicine from the University of Veterinary Medicine in Hannover, Germany and comparative biomedical sciences from Cornell University. She has received numerous honors and awards, including a Morris Animal Foundation fellowship training grant, and is the author of many peer-reviewed publications. Hoelzer is a member of the American Veterinary Medical Association, the Society for Risk Analysis, and the International Association for Food Protection. She serves as scientific editor for the Elsevier journal Research in Veterinary Science.
Jenny Tooth
Jenny is CEO of the UK Business Angels Association, the trade body for angel and early-stage investing, representing over 18,000 investors around the UK. Jenny has over 20 years’ experience of facilitating SMEs’ access to investment, both in the UK and internationally. She ran her own consultancy on access to finance for SMEs, including spending nine years based in Brussels, working closely with the EC. In 2009, Jenny co-founded Angel Capital Group which incorporates London Business Angels, one of the most established and active angel networks in the UK.
Jenny is an angel investor and in her role at UKBAA she focuses on building the angel community around the UK, connecting investors to good deal flow and assisting entrepreneurs to attract investors. Jenny sits on the steering group for emerging technologies and innovations for Innovate UK and the advisory board for the London Co-Investment Fund. Jenny is an experienced speaker on angel investing and entrepreneurship both in the UK and internationally. She has an MSc in Economics from the London School of Economics and Political Science. Jenny was awarded an OBE in 2015 for services to small businesses.
James M. Wilson
James M. Wilson, MD, PhD is a Professor in the Perelman School of Medicine at the University of Pennsylvania where he has been at the nexus of the field of gene therapy from its birth. Dr. Wilson began his work in gene therapy during his graduate studies at the University of Michigan over 30 years ago. He created the first and largest academic-based program in gene therapy after being recruited to Penn in 1993, initially focusing on the clinical translation of existing gene transfer technologies but soon redirecting his efforts to the development of second and third generation gene transfer platforms, the first of which was licensed to a biotechnology company he founded that resulted in the first, and only, commercially approved gene therapy in the western hemisphere.
More recently, his laboratory discovered a family of viruses from primates that could be engineered to be very effective gene transfer vehicles. Dr. Wilson has also been active in facilitating the commercial development of these new gene therapy platforms through the establishment of several biotechnology companies. He is currently leading a national dialogue on the challenges of commercializing these potentially lifesaving treatments due to the disruptive nature they will have on traditional business models. Throughout his career, the focus of Dr. Wilson's research has been rare inherited diseases, ranging from cystic fibrosis to dyslipidemias to a variety of metabolic disorders. He is the founder of a 501(c)3 called Health Through Fitness in Orphan Diseases and Director of a bicycle team called Rare Disease Cycling whose participants compete at a national level and help raise money for rare disease research.
Dr. Wilson has published over 550 papers, reviews, commentaries and editorials in peer-reviewed literature and is an inventor on over 117 patents. He was the second President of the American Society of Gene Therapy, the 2014 recipient of the William Osler Patient Oriented Research Award of the University of Pennsylvania and 2015 recipient of the Scientific Achievement Award
Dr. Henrik Bjørn Nielsen
Gudrun Ravetz
Currently Gudrun works as a Veterinary Consultant to Pet Health Plans from Denplan and as an external interviewer for prospective veterinary students at University of Liverpool. Alongside practicing as a small animal veterinary surgeon on graduating in 2002, Gudrun furthered her interest in the business side of the veterinary profession by studying for the post graduate certificate in business. Gudrun became President at the BVA Member’s Day and AGM on 22 September 2016.
